secwatch.observer — SEC 8-K summary
======================================

Issuer:     T2 Biosystems, Inc. (—)
CIK:        0001492674
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001193125-24-277962
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

T2 Biosystems receives Nasdaq delisting notice; hearing set for Jan 9, 2025
---------------------------------------------------------------------------

- Received Nasdaq letter on Dec 12, 2024 for bid price below $1.00 for 30 consecutive days under Rule 5550(a)(2).
- Previously on Nov 7, 2024, received notice of market value of listed securities below $35M (Rule 5550(b)(2)).
- Staff issued delist determination; company requested hearing and paid $20k fee, stay granted.
- Hearing scheduled for Jan 9, 2025; stock remains listed pending panel decision.
- No assurance of continued listing; failure to comply could lead to delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492674/000119312524277962/0001193125-24-277962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492674/000119312524277962/d849479d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-277962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer